WO2004103258A1

WO2004103258A1 - Nipple device

Info

Publication number: WO2004103258A1
Application number: PCT/JP2004/005628
Authority: WO
Inventors: Masaharu Inoue; Nobuaki Takamizu; Tatsuhiko Kan; Wakoto Bukawa; Takumi Watanabe
Original assignee: Combi Corporation
Priority date: 2003-05-20
Filing date: 2004-04-20
Publication date: 2004-12-02
Also published as: WO2004103257A1; JP4472635B2; EP1625843A4; KR101128968B1; AU2003234839A1; KR20060010779A; CN1791374A; EP1625843A1; JPWO2004103258A1; CN100418505C

Abstract

A nipple device (10), comprising a nipple (11) and a nipple holding body (15) holding the nipple (11), wherein a liquid permeable body (25) is installed in the nipple holding body (15), and a cap (17) is installed on the nipple holding body (15). A medicine container (20) covered by a film (21) is stored in the cap (17). When the cap (17) is installed on the nipple holding body (15), the projection (19) of the nipple holding body (15) pierces the film (21).

Description

Nipple placement technology

The present invention relates to a nipple device capable of administering a medicine to an infant.

Akira background technology

BACKGROUND ART Conventionally, as a method of administering a drug to a baby while sucking the pacifier, a diaper filled with a drug has been known (for example, Japanese Patent Application Laid-Open No. 2001-5111164) See). book

Such a pacifier has a mouthpiece, in which a tablet is placed in a void. Tablets are administered to infants by holding them in their mouths.

In the conventional pacifier described above, the tablets are placed in the vacant space of the mouthpiece, but when refilling the pacifier with tablets, the tablets must be placed in the vacant space of the mouthpiece, and the refilling operation is complicated. is there.

In addition, the pacifier needs to be cleaned regularly, but the pacifier is so integrated that the container cannot be cleaned. Disclosure of the invention

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a nipple device that can easily perform replenishment and cleaning of a medicine.

The present invention comprises a nipple, a nipple holder for holding the nipple, and a cap for engaging with the nipple holder, wherein a drug is filled in the cap and the nipple side is covered with a film. A nipple device comprising: a nipple holder; and a rupture portion for breaking the film when the cap is engaged with the nipple holder. The present invention is a nipple device characterized in that a nipple holder is provided with a liquid permeable body extending into the nipple, and a break portion of the nipple holder is formed of a projection for piercing a film. The present invention is a nipple device characterized in that an external screw is provided on a nipple holder and an internal screw is provided on a cap to engage with the external screw.

The present invention is the nipple device, wherein the liquid permeable body is composed of a plate-like body that comes into contact with the film of the medicine container portion, and a rod-like body extending from the plate-like body toward the nipple. The present invention is a nipple device characterized in that an opening is provided in a plate-shaped body of a liquid permeable body, and a projection projects from the nipple side to the medicine container section side through the opening.

The present invention is the nipple device characterized in that the medicine container portion is constituted by a medicine container provided in a cap.

The present invention is the nipple device, wherein the medicine container portion is formed of a region defined by a film in the cap.

The present invention provides a nipple device characterized in that the nipple holder has a communication space communicating with the inside of the nipple, and the communication space is provided on the medicine container side and is covered by a partition wall having a communication port. is there.

The present invention is the nipple device, wherein the rupture portion of the nipple holder is formed by an end of a partition wall.

The present invention is a nipple device characterized in that a one-way valve for allowing a medicine to flow from a medicine container portion to a nipple holder is provided at an opening of a partition wall.

The present invention includes a nipple, a nipple holder having a container storage part that holds the nipple and communicates with the nipple side, and a cap that is swingably attached to the nipple holder and covers the container storage part. A nipple device characterized in that a medicine container is filled with a medicine in the container housing and a medicine container having an opening on the nipple side is arranged.

The present invention is a teat device characterized in that a cylindrical guide projecting toward the nipple is provided in the container storage section, and the medicine container has a spout inserted into the cylindrical guide.

The present invention is the nipple device, wherein the medicine container is detachable from the container storage part, and the cap is provided with an engagement rib for engaging with the cylindrical guide of the container storage part. ·

The present invention is the nipple device characterized in that the medicine container is made of a flexible material and is fixed in the container accommodating portion, and a cap is provided with a pressing portion for crushing the medicine container. The present invention is the nipple device, wherein the medicine contains a xylitol component. 'The present invention is a teat device wherein the medicament comprises a virus capture composition. The present invention is the nipple device, wherein the virus-trapping composition contains, as active ingredients, a swallow-rich water extract and Z or swallow-rich enzyme-treated product. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a side sectional view showing a first embodiment of a nipple device according to the present invention. '

Figure 2 is an exploded view of the nipple device.

FIG. 3 is a view taken in the direction of the III line in FIG.

FIG. 4 is a side sectional view showing a nipple device according to a second embodiment of the present invention.

Figure 5 is an exploded view of the nipple device.

FIG. 6 is a perspective view showing a third embodiment of the nipple device according to the present invention.

Figure Ί is a partial sectional view of the nipple device.

FIG. 8 is a view showing a modification of the nipple device according to the present invention.

FIG. 9 is a view showing a modification of the nipple device according to the present invention.

FIG. 10 is a chart showing the results of examining the activity of the virus capturing composition to neutralize influenza virus infection.

FIG. 11 is a chart showing the results of examining the molecular species and content of sialic acid contained in the virus capturing composition.

FIG. 12 is a diagram showing the results obtained by separating the glycopeptides contained in the virus-trapping composition by SDS-PAGE and examining the binding to influenza virus. BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, embodiments of the present invention will be described with reference to the drawings.

1 to 3 are views showing a nipple device according to a first embodiment of the present invention. Among them, FIG. 3 is a view taken in the direction of the line III in FIG.

As shown in FIGS. 1 to 3, the nipple device 10 extends from the nipple 11 to the mouth of the baby, the nipple holder 15 for holding the nipple 11, and the nipple 11 from the nipple holder 15. It has a liquid permeable body 25 and a cap 17 that engages with the nipple holder 15. In the cap 17, there is provided a drug container (drug container section) 20 filled with a liquid drug, for example, a xylitol component for preventing tooth decay. The drug container 20. The nipple 11 side is covered with silver paper or resin film 21. Also, when the cap 17 engages with the nipple holder 15, a projection 19 piercing the film 21 of the medicine container 20 is provided on the nipple holder 15. The projection 19 functions as a rupture portion for breaking the film 21 when the cap 17 is engaged with the nipple holder 15.

Next, the components of each part will be described in more detail. First, the nipple 11 has a cylindrical nipple body 1 la and a plate-shaped base portion 1 lb provided at the base end of the nipple body 11. The nipple main body 11a is provided with an opening 12 for supplying a drug sent through the liquid permeable body 25 to the outside.

The nipple holder 15 has a cylindrical portion 15a and a large-diameter portion 15b having a larger diameter than the cylindrical portion 15a. The proximal end 1 lb of the nipple 1 1 is inserted into the large-diameter portion 15 b of the nipple holder 15, and the holding frame 13 is inside the large-diameter portion 15 b from outside the proximal end 1 lb. It fits in. Thus, the nipple 11 is held by the nipple holder 15.

The medicine container 2Q is adapted to enter the cylindrical portion 15a of the nipple holder 15, and the medicine container 20 is joined to the cap 17.

The nipple 11 side of the medicine container 20 is covered with the film 21 as described above, and the film 21 is easily pierced and damaged by the projection 20 of the nipple holder 15. The fluid permeable body 25 has the same shape as the film 21 of the medicine container 20 and has a disc-shaped plate 25 b in contact with the film 21 and a nipple 1 from the plate 25 b. And a bar 25a extending to one side. The liquid permeable body 25 is made of a sponge material as a whole, and allows the medicine in the medicine container 20 to permeate the nipple 11 side.

The plate 26b of the liquid permeable body 25 has an opening 26 formed below the rod 25a. The liquid permeable body 25 can be positioned and fixed by the nipple holder 15 by attaching the projection 19 of the nipple holder 15 to the opening 26 of the plate-like body 25b. The rod-shaped body 25a of the liquid permeable body 25 preferably has the same outer shape as the inner shape of the nipple body 11a of the nipple 11, and in this case, the liquid permeable body 25 is connected to the nipple. Positioning and fixing can be performed by the body 11a.

The projection 19 of the nipple holder 15 is held between the cylindrical portion 15a and the large-diameter portion 15b, and the tip of the drug container 20 on the film 21 side is pointed. .

An outer screw 16 is provided on the outer surface of the cylindrical portion 15a of the nipple holder 15, and an inner screw 18 for engaging the outer screw 16 is provided on the inner surface of the cap 17. However, the cylindrical portion 15a and the cap 17 may be engaged with each other by a one-touch fitting instead of screw engagement.

In any case, the cylindrical portion 15a of the nipple holder 15 and the cap 17 are engaged with each other in a sealed state.

Next, the operation of the present embodiment having such a configuration will be described.

First, as shown in FIG. 2, the projection 19 of the nipple holder 15 is inserted into the opening 26 of the plate-like body 25b of the liquid permeable body 25.

Next, the base end 11b of the nipple 11 is fitted into the large diameter portion 15b of the nipple holder 15, and the holding frame 13 is further fitted into the large diameter portion 15b. The nipple 11 is held by the nipple holder 15.

In this case, it is preferable that a sealing material is interposed between the large-diameter portion 15. B of the nipple holder 15 and the holding frame 13. The projection 19 of the nipple holder 15 is inserted into the opening 26 of the liquid permeable body 25, and the rod 25a of the liquid permeable body 25 comes into contact with the inner surface of the nipple body 11a. As a result, the liquid permeable body 25 is positioned and fixed by the nipple holder 15 and the nipple 11.

Next, the inner screw 18 of the cap 17 is engaged with the outer screw 16 of the nipple holder 15, and the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15. In this case, a medicine container 20 is attached in advance to the cap 17 with an adhesive, and when the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15, the film of the medicine container 20 is formed. 21 is pierced by the projection 19 of the nipple holder 15 and is damaged.

When the film 21 is broken, the liquid drug (including the xylitol component) in the drug container 20 moves to the nipple 11 via the liquid permeable body 25. When the infant holds the nipple 11, the drug that has been transferred to the nipple 11 by the liquid permeant 25 enters the infant's mouth through the opening 12 in the nipple body 11 a, and the caries are formed by xylitol. Prevention can be achieved.

When the medicine in the medicine container 20 is completely consumed, the cap 17 and the medicine container 20 are removed from the nipple holder 15, and a new medicine container 20 having a medicine container 20 filled with the medicine in advance is prepared. A cap 17 is attached to the nipple holder 15.

After the nipple device 10 has been used for a long time, each component can be disassembled by the reverse method to clean each component (see FIG. 2).

As described above, according to the present embodiment, when the medicine in the medicine container 20 is consumed, the new medicine container 20 and the cap 17 are simply attached to the nipple holder 15, which is easy and simple. Can be refilled. In addition, it is possible to easily clean each component only by disassembling each component.

Next, a second embodiment of the nipple device according to the present invention will be described with reference to FIGS. Note that, in the second embodiment shown in FIGS. 4 and 5, the same parts as those in the first embodiment shown in FIGS. 1 to 3 are denoted by the same reference numerals, and detailed description is omitted.

As shown in FIGS. 4 and 5, the nipple device 10 is composed of a nipple 11 held by a baby, a nipple holder 15 holding the nipple 11, and a cap 17 engaged with the nipple holder 15. And

A film 21 is provided in the cap 17. In the cap 17, an area 30 ′ defined by the film 21 is filled with a liquid drug, for example, a liquid drug containing a xylitol component for preventing tooth decay. In this case, a region 30 defined by the film 21 in the cap 17 forms a medicine container portion.

Also, when the cap 17 engages with the nipple holder 15, the end (break portion) 15 d of the partition wall 15 c of the nipple holder 15 described later breaks the film 21. ing.

By the way, the nipple holder 15 has a cylindrical portion 15a and a large-diameter large-diameter portion 15b provided on one side of the cylindrical portion 15a, and the other side of the cylindrical portion 15a. The above mentioned partition wall 1 5c Is provided.

The nipple holder 15 having such a configuration has a communication space 33 communicating with the inside of the nipple 11 therein, and the communication space 33 is covered by the partition wall 15c described above. A communication port 31 is provided in the partition wall 15c, and a one-way valve 32 is attached to the surface of the partition wall 15c on the side of the communication space 33 so as to open and close the communication port 31 freely. ing. The one-way valve 32 allows the medicine in the region 30 to flow into the communication space 33, and the medicine in the communication space 33 cannot move to the region 30 side.

First, as shown in FIG. 4, the base end 11b of the nipple 11 is fitted into the large-diameter portion 15b of the nipple holder 15, and the holding frame 13 is further inserted into the large-diameter portion 15b. The nipple 11 is held by the nipple holder 15.

Next, the inner screw 18 of the cap 17 is engaged with the outer screw 16 of the nipple holder 15, and the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15. In this case, the region 30 defined by the film 21 in the cap 17 is filled with a drug in advance, and when the cap 17 is fitted into the cylindrical portion 15a of the nipple holder 15, The film 21 in 17 is broken by the end 15 d of the partition wall 15 c of the nipple holder 15.

When the film 21 breaks, the medicine in the area 30 flows into the communication space 33 of the nipple holder 15 through the communication port 31 and the one-way valve 32, and then the medicine in the communication space 33 is removed. Move to nipple 1 1 side.

When the infant holds the nipple 11, the drug that has migrated to the nipple 11 enters the infant's mouth through the opening 12 and the xylitol component can prevent tooth decay.

If all of the medicine in the area 17 of the cap 17 has been consumed, the cap 17 is removed from the nipple holder 15 and a new cap 17 prefilled with the medicine is placed on the nipple holder 15. Mounted. .

After the nipple device 10 has been used for a long time, each component is disassembled by the reverse method, and each component is cleaned (see FIG. 5).

As described above, according to the present invention, when a medicine is consumed, the work of refilling the medicine is facilitated. In addition, the cleaning operation can be easily performed by disassembling the respective constituent members.

Next, a third embodiment of the nipple device according to the present invention will be described with reference to FIGS.

As shown in FIGS. 6 and 7, the nipple device 10 is a nipple holder 1 having a nipple 11 held by a baby and a container storage portion 33 holding the nipple 11 and communicating with the nipple 11 side. 5 and a cap 42 that is swingably attached to the nipple holder 15 and covers the container storage section 43.

Of these, the nipple 11 has a hollow shape, and a fluid drug filled in the drug container 45, for example, a drug containing a xylitol component for preventing tooth decay is sent and stored therein, as described later. . The nipple 11 is provided with an opening 12 for supplying the drug stored therein to the outside.

The nipple holder 15 has a flange 40 for holding the nipple 11 and a flange cover 41 provided on the flange 40, and the container storage portion 43 is provided in the flange cover 41. ing.

The container storage section 43 provided on the flange cover 41 has an upper opening, and a medicine container 45 filled with a liquid drug is stored in the container storage section 43. The container storage section 43 is provided with a cylindrical guide 11 protruding toward the nipple 11, and the container storage section 43 communicates with the nipple 11 via the cylindrical guide 44.

Incidentally, the cap 42 is swingably attached to the flange cover 41 of the nipple holder 15 via the driving shaft 42a so as to cover the container housing portion 43 from above. An engagement rib 48 is provided on the inner surface of the cap 42 to engage with the upper end of the cylindrical guide 44. When the container 42 is covered by the cap 42, the engaging rib 48 is inserted into the container 43 and engaged with the upper end of the cylindrical guide 44.

In this case, the upper end of the cylindrical guide 44 has a tapered shape tapering downward, and the tip 48 a of the engaging rib 48 corresponds to the upper end of the cylindrical guide 44. It has a tapered shape that tapers downward. Preferably, the engagement rib 48 is made of a flexible material. Further, the inside of the medicine container 45 is filled with a liquid medicine, and the medicine is detachably stored in the container storage part 43. That is, the medicine container 45 is made of a flexible material as a whole, and has a container body 45a for accommodating a medicine and a spout 46 made of a hard material provided at the lower end of the container body 45a. are doing. The spout 46 of the medicine container 45 has an external thread 46a formed on the outer surface thereof.The spout 46 has an external thread 46a inside the cylindrical guide 44 of the nipple holder 15. It is inserted by screwing into the inner screw (not shown) of 4.

The spout 46 may be fitted into the cylindrical guide 44 without forming an external thread on the outer surface of the spout 46. .

6 and 7, before use, first remove the cover 47 screwed into the spout 46 of the medicine container 45, and remove the medicine container 45 from the container storage section 43 of the nipple holder 15. To be stored. In this case, the medicine container 45 is firmly fixed in the container storage portion 43 by screwing the external screw 46 a of the spout 46 of the medicine container 45 into the inner screw of the cylindrical guide 45. it can.

Next, the container body 45 a made of a flexible material of the medicine container 45 is pressed upward and pressed, and the medicine in the container body 45 a is supplied to the nipple 11 side via the spout 46 and the cylindrical guide 44. I do. After that, the medicine container 45 is removed from the container storage section 43, the cap 42 is swung via the drive shaft 42 a, and the container storage section 43 is sealed by the cap 42. At this time, the engaging rib 48 provided on the inner surface of the cap 42 engages with the upper end of the cylindrical guide 44 to completely seal the upper end of the cylindrical guide 44.

Since the engaging rib 48 is entirely made of a flexible material, the upper end of the cylindrical guide 44 can be reliably sealed by the tip 48 a of the engaging rib 48. When the infant holds the nipple 11, the medicine in the nipple 11 enters the infant's mouth from the dent 12 of the nipple 11, and can prevent tooth decay by the xylitol component. Next, a modification of the embodiment shown in FIGS. 6 and 7 will be described with reference to FIGS. In the embodiment shown in FIGS. 8 and 9, the medicine container 45 is fixed to the container storage portion 43.

8 and 9, the same parts as those in the embodiment shown in FIGS. 6 and 7 are denoted by the same reference numerals, and detailed description thereof will be omitted. As shown in FIG. 8, the medicine container 45 has a container body 45 a made of a bristle-like flexible material filled with a medicine, and a spout 46 provided at the lower end of the container body 45. ing.

The nipple holder 15 for holding the nipple 11 has a flange 40 and a container storage section 43 provided on the flange 40.

The container storage section 43 accommodates a medicine container 45 therein, and a cylindrical guide 44 protruding toward the nipple 11 is provided at a lower portion of the container storage section 43. o

Further, the container storage portion 43 has an upper opening, and a cap 42 for covering the storage portion 43 is movably attached to the container storage portion 43. Further, on the inner surface of the cap 42, a pressing portion 49 for pressing the bellows-like container body 45a is provided.

In FIG. 8, the medicine container 45 is accommodated in the container accommodating portion 43 of the nipple holder 15, and at the same time, the spout 46 of the medicine container 45 is inserted into the cylindrical guide 44.

At this time, an external thread is formed on the outer surface of the spout 46 of the medicine container 35, and an internal thread is formed on the inner surface of the cylindrical guide 44, so that the spout 46 is screwed into the cylindrical guide 44 to thereby dispens the medicine. The container 45 can be firmly fixed to the container storage section 43. Next, the cap 42 is swung to cover the container storage section 43 with the cap 42. In this case, the container body 45a of the medicine container 45 is pressed by the pressing portion 49 of the cap 42, and the medicine in the container body 45a passes through the spout 46 and the cylindrical guide 44 and the nipple 1 Sent to one side.

Next, a further modification of the present invention will be described with reference to FIG. In the modification shown in FIG. 9, the medicine container 45 has a medicine container-filled container body 45a and a spout 46 provided at the lower end of the container body 45. In this case, the container body 45a is not in the shape of a bellows, has a thin shape, and is made of a flexible material.

In FIG. 9, the medicine container 45 is stored in the container storage section 43 of the nipple holder 15. At this time, an external thread may be formed in the spout 46 of the medicine container 45, an internal thread may be formed in the cylindrical guide 44, and the spout 46 may be screwed into the cylindrical guide 44. Next, the cap 42 is swung to cover the container storage section 43 with the cap 42, The container body 45 a of the medicine container 45 is pressed by the pressing portion 49. As a result, the medicine in the container body 45 can be sent to the nipple 1 ljlj via the spout 46 and the cylindrical guide 44.

Next, a fourth embodiment of the nipple device according to the present invention will be described with reference to FIGS.

The embodiment shown in FIGS. 10 to 12 is different from the embodiment shown in FIGS. 1 to 12 only in that a drug containing a virus capturing composition is used instead of a drug containing a xylitol component as a liquid drug. This is substantially the same as the embodiment shown in FIG.

That is, instead of the drug containing the xylitol component, the drug containing the virus capturing composition is filled in the drug container 20 shown in FIGS. 1 to 3, and the region 17 of the cap 17 shown in FIGS. 4 and 5 is filled. Within 0, the drug containing the virus capture composition is filled instead of the drug containing the xylitol component. Further, the medicine container 45 shown in FIGS. 6 to 9 is filled with a medicine containing a virus-trapping composition instead of a medicine containing a xylitol component.

Next, the virus capturing composition will be described in detail. The virus-trapping composition contains, as active ingredients, a water extract of swallow fossa and an enzyme-treated product of fossil or swallow fossil.

Of these, swallow fossils are nests that make swallows their own saliva into filaments, and have been eaten as a high-quality ingredient in China for a long time, as well as for lung disease, healthy stomach, expectorant, skin rejuvenation, and tonic nutrition. It is also used as a food with medical effects. Its components are high in protein and carbohydrates, and almost free of lipids.

Commercially available swallow fossils include those collected in natural caves (cave nest) and those cultured indoors (house nest), both of which can be used. In addition, there are various types, from those that only remove dirt such as hair and feces from the collected swallow fossils and those that are washed, and those that collect the swallow fossils and form them by repeating bleaching and washing. It is preferable to use swallow fossa that has not been washed or bleached.

The swallow fossil water extract of the present invention can be obtained, for example, as follows. A swallow fossa crushed to a size of 2 mm or less, preferably 150 zm or less After adding 0 to 100 times the amount of water and extracting the mixture by standing or stirring at 1 to 100 ° C. for 0.5 to 48 hours, the mixture is filtered to obtain a filtrate. The filtrate may be used as it is or may be appropriately concentrated to obtain a concentrated solution, which can be used as the virus capturing composition of the present invention. These may be freeze-dried or spray-dried to be powdered.

In addition, the enzyme-treated product of the swallow fossa was extracted by adding water or hot water in an amount of 10 to 10,000 times its mass to the swallow fossil crushed to the same size as above and extracting it in the same manner as above. The solution (the solution before filtration), the filtrate obtained by filtering the extract, or the solution obtained by heat-treating the extract at 60 to 130 ° C. for 5 to 30 minutes can be obtained by enzyme treatment.

As the above-mentioned enzyme, protease is preferable, and for example, one that is commercially available as an enzyme for food can be used alone or in combination of two or more. Specifically, “Pancreatin F” (trade name, manufactured by Amano Pharmaceutical Co., Ltd.), “Aloase AP-10” (trade name, manufactured by Yakult Yakuhin Kogyo), “Papain Solble” (trade name, manufactured by Yakult Yakuhin Kogyo) ), "Heat-resistant Proteaze Samoa" (trade name, manufactured by Daiwa Kasei) and the like.

The conditions for the enzyme treatment are not particularly limited, and the pH of the solution is adjusted to the optimal pH of the enzyme to be used, an appropriate amount of the enzyme is added, and the mixture is reacted at the optimal temperature of the enzyme for 0.5 to 24 hours. Thereafter, the enzyme may be inactivated by heat treatment or the like. The filtrate obtained by filtering this reaction solution can be used as it is, or can be appropriately concentrated to obtain a concentrated solution, which can be used as the virus capturing composition of the present invention. Further, these may be freeze-dried or spray-dried to be powdered.

The average molecular weight of the enzyme-treated product is preferably 500 to 200,000, more preferably 20,000 to 70,000.

The virus-trapping composition of the present invention comprises, in addition to the swallow fossil water extract obtained as described above or an enzyme-treated product thereof, functional food materials such as various sugars, lactic acid bacteria, bifidobacteria, polyphenols, and oligosaccharides; It can contain ingredients such as proteins, fatty acids, minerals, vitamins, dietary fiber, sugar alcohols, surfactants, and preservatives.

The form of the virus capturing agent of the present invention is not particularly limited, but is preferably a solution or a jelly. In addition, the virus-trapping composition is a food-derived component, and therefore has high safety, and can be directly used on the human body as an inhalant or the like. The content of the water extract of swallow fossa and / or enzymatically treated swallow fossil in the virus-trapping composition of the present invention is preferably 0.1 to 10 000 zg / mL, more preferably 0.2 400 zg / mL.

Each sample as shown in Table 1 was prepared and used for the following tests.

table 1

(1) Infection neutralization test

By measuring the activity of lactate dehydrogenase (LDH) released from MDCK (Madian-Darby Canine Kidney) monolayer cells infected with influenza virus, the degree of cell membrane destruction by human influenza virus was measured (C- T Guo, CH Wong, T Ka imoto, Τ Miura, Υ Ida, LR Juneja, MJ Kim, H Masuda, TS uzuki, and Y Suzuki .Synthetic sialylphosphatidyl-ethanolamine derivatives bind to human influenza A viruses and inhibit viral infection.Glycoconjugate J 1998, 15 (11): 1099-1108).

About; L 00TCID ₅₀ (50% Tissue-Culuture Infectious Dose 50% tissue culture infectious dose) influenza virus (A / PR / 8/34 (H1N1) or A / Aichi / 2/68 (H3N2)), and An EMEM medium (Eagles Minimum Essential Medium) containing each sample shown in Table 1 (final concentration 15000 1g / mL) was inoculated into monolayer cultured MDCK cells in a 96-well Thai Yuichi plate (flat bottom). 5 hours at 5 ° C Cultured.

After the culture, the liquid was removed, and the cells were suspended in 100 L of the same medium. After further culturing at 34.5 ° C for 20 hours, 12.5 zL of the obtained culture was diluted 4-fold with lO OmM Tris-HCl buffer (pH 8.2), and the reaction was performed at 50 / L. Solution (2 mM NAD, 20 Om-unit / mL diaphorase, 190 mM lithium lactate, 0.78 mM nitro blue tetrazolium, 10 OmM Tris-HCl buffer (ρΗ8'.2)) did. After incubation at 37 ° C for 10 minutes, the reaction was stopped by adding 100 M of 0.5 M hydrochloric acid. LDH activity was determined by measuring the absorbance at 550 nm (control: 630 nm). Fetuin was used as a positive control. Fetuin is a component contained in fetal bovine serum and is known to have influenza neutralizing activity. Fig. 10 shows the results.

As shown in FIGS. 10 (A) and (B), the IC ₅₀ for human influenza virus of sample 1 (A / PR / 8/34 (H1N1) and A / Aichi / 2/68 (H3N2)) was SO jug / mL, indicating that the inhibitory activity was 2 to 8 times stronger than that of fetuin used as a positive control. On the other hand, it was found that Sample 2 had almost the same inhibitory activity against human influenza virus (A / PR / 8/34 (H1N1)) as that of fein. '

For each of the above samples, use MDCK monolayer cells to dilute 2-fold EMEM medium containing swallow fossa solution (5 mg / mL starting concentration) in a 96-well Thai-Yuichi plate (flat bottom). The cells were cultured at 37 ° C for 25 hours in addition to the cultured MDCK cells, and the resulting culture was measured for lactate dehydrogenase (LDH) activity to determine if it was cytotoxic. The sample showed no cytotoxicity to MDCK cells, indicating high safety.

(2) Hemagglutination inhibition test

Dispense 25 µL of PBS into each well of a 96-well Thai-Yuichi plate (U bottom), place 25 zL of the test sample (sample 2) solution in the first row of the Thai-Yuichi plate, and use a micropipette. Was performed several times. The 25 / L in the first row was transferred to the second row, and aspirated and discharged several times with a micropipette. This operation was performed in the same manner as the third and fourth rows to prepare a two-fold dilution series. After dispensing 25 solutions containing each virus shown in Table 2 into each well, the plate was gently shaken in the evening, and then left at 4 ° C for 6 ° C. Then, 0.5% (V / V) human erythrocyte suspension was dispensed into each well by 5 and the evening

-Gently shake the plate, and then leave it at 4 ° C for 60 minutes, then determine the presence or absence of agglutination by the sedimentation state of red blood cells at the bottom of each well, and determine the minimum agglutination inhibition of each sample. The concentration was calculated. The results are shown in Table 2.

Table 2

As shown in Table 2, sample 1 was tested against influenza viruses tested (viruses isolated from humans, birds and birds) except for A / Swine / Colorado / 1/77 (H3N2). It can be seen that hemagglutination is inhibited at very low concentrations. On the other hand, it can be seen that Sample 2 exhibits hemagglutination inhibitory activity at a low concentration against viruses other than A / Memphis / 1/71 and A / Swine / Colorado / 1/77 (H3N2). From the above results, it was found that Samples 1 and 2 had the ability to adsorb a wide variety of influenza viruses. (3) Molecular species and content of sialic acid contained in Samples 1 and 2 It has been clarified that influenza virus recognizes and binds to specific sugar chains containing sialic acid. Therefore, the molecular species and content of sialic acid in the swallow fossa were examined by the following method (Hara, S., Yamaguchi, Μ ·, Takemori, Y., Nakamura, M., Ohkura, Y .: Highly sensitive determination of N). -acetyl-and N-glycol ylneuraminic acids in human serum and urine and rat serum by reverse d-phase liquid chromatography with fluorescence detection.J. Chroma togr 377, 111-119 (1980), Hara, S., Takemori, Y ., Yamaguchi, M. Nakamura, M., Ohkura, Y .: Fluorometric high-performance liquid chroma tography of N-acetyl and Ν-glycolylneuraminic acids and its applicat ion to their microdetermination inn human and animal sare. Analytica 1 Biochem. , 164, 138-145 (1987)).

That is, each sample was heated in 20 L of 2 M acetic acid at 80 C for 3 hours to hydrolyze the glycoside bonds of sialic acid, and then the fluorescent reagent (Sodium hydrosulfate 15.7 mg, 2-mercaptoethanol 350 / L and 20 / L of diamino4,5-methylenedioxybenzene 2HC1 (hereinafter referred to as DMB, Dojin Chemical Co., Ltd., adjusted to 5 mL with water) was added, and heated at 50 ° C for 2.5 hours in the dark.

From this reaction solution, 10 L of the fluorescent derivative of sialic acid was separated by HP LC using a C0SM0SIL / C0SM0GEL column (trade name, manufactured by Nacalai Tesque, Inc.), and a spectrofluorometer (trade name “650- 10S ”manufactured by HITACHI). Fig. 11 shows the results. As shown in FIG. 11, both Sample 1 and Sample 2 contained sialic acid, and N-acetylneuraminic acid (NeuAc) was found to be the major molecular species. In addition, it was found that N-glycolylylamic acid (NeuGc) was also contained although the ratio was small. In addition, the N-acetylneuraminic acid content (12.5%) of sample 1 was about twice as high as that of sample 2 (6.52%), and the N-glycolylylamic acid content was The value was 0.41% for sample 1 and 0.09% for sample 2.

These results suggest that sialic acid contained in sample 2 is very similar to human sialic acid species, and that proteins, peptides or lipid molecules containing these sialic acids are components that bind to influenza virus. Was done. In addition, sample 1 showed higher influenza virus binding activity and infection inhibitory activity than sample 2, but this fact is well correlated with the fact that sample 1 has a higher sialic acid content than sample 2. This also suggests that the sialic acid-containing molecules in the sample have anti-influenza activity.

(4) Binding of influenza virus to glycopeptides separated by SDS-acrylamide gel electrophoresis (SDS-PAGE) was examined by the following method (Takashi Suzuki, Mikiko Tsukimoto, Masato Kobayashi, Akira Yamada, Yos hihiro Kawaoka, Robert G. Webster, Yasuo Suzuki: Sialoglycoproteins that Bind Influenza A Virus and Resist Viral Neuraminidase in Different Animal Sera. J. Gen. Virology, 75, 1769-1774 (1994)).

That is, a sample 1 or sample 2 (0.2 mg) dissolved in PBS was mixed with an equal volume of SDS-PAGE sample preparation buffer (2% SDS, 10% glycerin, 0.001% Bromphenol Blue, containing 0%). 0625M Tris buffer, pH 6.8). Each sample was treated in a boiling water bath for 5 minutes. Under non-reducing conditions, 10-20% SDS-polyacrylamide (SDS-PAGE plate: trade name "ET-1020L", manufactured by ATTO Corporation) ).

The glycopeptide spread on the gel was transferred to a polyvinylidene difluoride (PVDF) membrane (Daiichi Kagaku) (powered at 2 mA / cm for 30 minutes), and a 5% solution of ischemic albumin (BSA) —PBS solution ( (0.2 mL / cm) at 4 ° C for 15 hours. ' After washing the PVDF membrane 5 times with PBS, add the influenza virus prepared in 2 HAU-0.25% BS A_PBS suspension and gently calm at 4 ° C for 15 hours to avoid the influence of virus neuraminidase. Was shaken. Thereafter, the virus suspension was removed, the PVDF membrane was washed 5 times with PBS, and an anti-influenza antibody was added thereto, followed by shaking at 4 ° C for 2 hours. The antibody solution was removed, the PVDF membrane was washed 5 times with PBS, and a 0.25% BSA-PBS solution of ABC (Peroxidase) Kit (trade name, manufactured by Vector Laboratories, Inc.) of VECTASTAIN Kit was added. Shake at ° C for 2 hours. After washing this PVDF membrane 5 times with PBS, add 10 mL of 0.1 M acetic acid (pH 6.0) to the color developing solution (200 mM L-acetonitrile solution of 110 mM 4-chloro-1-naphthol, 6 OmM N, N-diethyl- p-phenylenediamine-dihydrochlori Virus binding was examined using acetonitrile solution of de (200 zL, 31% hydrogen peroxide solution 1 // L). Figure 5 shows the results.

As shown in FIG. 12, the bands binding to influenza virus (A / Aichi / 2/68 (H3N2), A / Memphis / 1/71 (H3N2)) were both present in sample 1 and sample 2 (arrows in the figure). The band indicated by) was confirmed. On the other hand, in a control experiment (Virus (-)) in which all the other operations were treated in the same manner without adding a virus, no band binding to the virus could be confirmed. It was considered a peptide. In addition, although the degree of staining of bands by Coomassie brilliant blue (CBB) (which can stain proteins and peptides) is almost the same for both samples 1 and 2, the binding of virus to sample 1 is higher for sample 2 than for sample 2. It is clear that there are many types. From this result, it was clarified that in Sample 1, the sialic acid-containing glycopeptide that binds to the influenza virus was contained more abundantly than in Sample 2.

The virus-trapping composition of the present invention is highly safe because it contains food-derived components as active ingredients, and has an ability to adsorb various types of viruses. Can be used as In addition, by sending the virus capturing composition from the nipple 11 of the nipple device 10 into the mouth of the baby, it is possible to prevent viral infection of the baby.

Claims

The scope of the claims

1. Nipple and

A nipple holder that holds the nipple,

A cap that engages the nipple holder,

In the cap, a medicine container part filled with medicine and the nipple side is covered with a film is provided,

A nipple device, wherein the nipple holder is provided with a rupture portion for breaking the film when the cap is engaged with the nipple holder.

2. Provide the nipple holder with a liquid permeable body extending into the nipple,

2. The nipple device according to claim 1, wherein the rupture portion of the nipple holder is formed of a projection that pierces the film. ,

3. The nipple device according to claim 1, wherein an external thread is provided on the nipple holder, and an internal thread is provided on the cap to engage with the external thread.

4. The nipple device according to claim 2, wherein the liquid permeable body is composed of a plate-like body that comes into contact with the film of the medicine container portion, and a rod-like body extending from the plate-like body toward the nipple.

5. The nipple device according to claim 4, wherein an opening is provided in the plate-shaped body of the liquid permeable body, and the projection projects from the nipple side to the medicine container section side through the opening.

6. The nipple device according to claim 1, wherein the medicine container section comprises a medicine container provided in a cap.

7. The nipple device according to claim 1, wherein the medicine container portion is formed of a region defined by a film in the cap.

8. The nipple holder has a communication space communicating with the nipple,

2. The nipple device according to claim 1, wherein the communication space is covered by a partition wall provided on the medicine container section side and having a communication port.

9. The nipple device according to claim 8, wherein the broken portion of the nipple holder is formed by an end of a partition wall.

10. The nipple device according to claim 8, wherein a one-way valve is provided at an opening of the partition wall to allow the medicine to flow from the medicine container to the nipple holder.

1 1. Nipples and

A nipple holder having a container storage part that holds the nipple and communicates with the nipple side; and a cap that is swingably attached to the nipple holder and covers the container storage part, and the medicine is filled in the container storage, A nipple device comprising a medicine container having an opening on the nipple side.

1 2. A cylindrical guide projecting toward the nipple is provided in the container

The teat device according to claim 11, wherein the medicine container has a spout inserted into the cylindrical guide.

1 3. The medicine container is removable from the container storage section.

13. The nipple device according to claim 12, wherein the cap is provided with an engagement rib that engages with the cylindrical guide of the container storage section.

14. The nipple device according to claim 12, wherein the medicine container is made of a flexible material and is fixed in the container housing portion, and the cap has a pressing portion for pushing the medicine container.

5. The method according to claim 1, wherein the drug contains a xylitol component. The nipple device according to any one of the above.

16. The nipple device according to any of claims 1 or 11, wherein the medicament comprises a virus capture composition.

17. The teat device according to claim 16, wherein the virus-trapping composition contains a water extract of swallow fossa and / or an enzyme-treated product of swallow fossa as an active ingredient.